April 13, 2026
Introduction: A New Minimally Invasive Approach to Prostate Tissue Ablation
For men diagnosed with localized prostate cancer, treatment decisions
often involve balancing effective cancer control with preservation of urinary
and sexual function. Traditional options such as surgery and radiation are
highly effective but can impact surrounding structures critical to quality of
life.
Vanquish® Water Vapor Ablation is an emerging, minimally invasive
treatment designed to address this challenge. By using targeted thermal energy
delivered through sterile water vapor, this approach aims to ablate prostate
tissue while minimizing damage to adjacent nerves and structures. As clinical
experience grows, Vanquish is becoming an important addition to the spectrum of
prostate cancer treatment options.
What Is Vanquish Water Vapor Ablation?
Vanquish Water Vapor Ablation is a transurethral, image-guided procedure
that uses high-energy sterile water vapor to destroy targeted prostate tissue.
The system delivers convective thermal energy directly into the prostate, where
it spreads only within the natural boundaries of the prostate capsule to
achieve controlled tissue ablation.
Unlike surgery, there are no incisions. Unlike radiation, there is no
exposure to ionizing energy over multiple sessions. Instead, Vanquish is
designed as a single-session, minimally invasive therapy performed
through the urethra.
This approach is part of a broader category of focal therapies, where the
goal is to treat known areas of cancer while preserving as much normal prostate
tissue and function as possible.
How Does the Vanquish Procedure Work?
Consultation and Evaluation
Before treatment, patients undergo a detailed evaluation including PSA
levels, biopsy results, and multiparametric MRI imaging. This allows the care
team to determine whether the cancer is localized and suitable for a targeted
treatment approach.
Treatment Planning
Imaging is used to map the prostate and identify areas requiring
treatment. This step is critical in ensuring precise delivery of therapy to
cancerous tissue while preserving surrounding structures.
Transurethral Vapor Delivery
During the procedure, the patient is asleep under anesthesia. The
Vanquish system is inserted into the urethra. Using live ultrasound and MRI guidance,
the physician delivers controlled doses of sterile water vapor directly into
the targeted areas of the prostate.
The vapor releases thermal energy that ablates prostate tissue in a
highly controlled fashion, with the goal of confining treatment to the intended
region. This causes less injury to the nerve bundles, which are responsible for
urinary and sexual function, compared to more radical treatments like radical prostatectomy or radiation. It also causes less damage to the urethral
sphincter, minimizing urinary incontinence recovery.
Procedure Time and Recovery
The procedure is typically completed in a single session under
anesthesia. The procedure generally takes about 30 to 45 minutes. Patients go
home the same day. A urethral Foley catheter is often placed at the time of the
procedure to prevent urinary retention. The Foley is typically removed within
3-5 days. Aside from the catheter, men are able to return to normal daily
activities within a few days.
Because the treatment is minimally invasive and avoids incisions,
recovery is generally faster than traditional surgical approaches.
Follow-Up Care
Post-treatment monitoring includes PSA testing, MRI scans, and often a
follow-up biopsy to ensure the cancer has been successfully treated.
Who Is a Candidate for Vanquish?
Vanquish Water Vapor Ablation is being evaluated primarily for men with localized
prostate cancer, particularly those who:
- Have low- to intermediate-risk
disease
- Have cancer identifiable on MRI
and confined to a specific region of the prostate
- Prefer a minimally invasive
treatment option
- Place a high value on preserving
urinary continence and sexual function
As with other focal therapies, careful patient selection is essential.
Men with more extensive or high-risk disease may be better suited for surgery,
radiation, or multimodal treatment approaches.
Clinical Data and the VAPOR 2 Trial
Vanquish Water Vapor Ablation is currently being studied in the ongoing VAPOR
2 pivotal clinical trial, which is evaluating its safety and effectiveness
in treating prostate tissue.
Early data from the trial has been encouraging:
- At 6 months, approximately
91% of patients achieved clearance of clinically significant
in-field disease (Grade Group 2 or higher) after a single treatment
- The procedure has demonstrated a favorable
safety profile, with no device-related serious adverse events reported
- Rates of urinary incontinence and
erectile dysfunction have been low in early follow-up
These preliminary results suggest that Vanquish may offer meaningful
cancer control while maintaining a strong quality-of-life profile. However,
longer-term data is still being collected, and ongoing follow-up will be
important in defining its role relative to established treatments.
Potential Advantages of Vanquish
Vanquish introduces several potential advantages compared to traditional
treatment approaches:
- Minimally invasive: No incisions and typically
performed as an outpatient procedure
- Single-session treatment: Avoids the prolonged treatment
schedule of radiation
- Targeted therapy: Focuses treatment on specific
areas of disease
- Function preservation: Designed to reduce the risk of
urinary incontinence and erectile dysfunction
- Repeatable and compatible with
future treatments: Does not eliminate the option for surgery or radiation if needed
later
These characteristics make it an appealing option for appropriately
selected patients seeking effective treatment with reduced impact on daily
life.
Important Considerations
While early results are promising, it is important to understand that
Vanquish is a relatively new technology.
- The system has received FDA
clearance for thermal ablation of prostate tissue
- It has not yet been fully
evaluated for long-term prostate cancer outcomes
- Ongoing clinical trials,
including VAPOR 2, will help define durability and long-term effectiveness
For this reason, treatment decisions should be made with a clear understanding of both the potential benefits and the evolving nature of the data.
Conclusion
Vanquish Water Vapor Ablation represents an innovative approach to
prostate cancer treatment, offering a minimally invasive, targeted alternative
for men with localized disease. With encouraging early results from the VAPOR 2
trial and growing clinical adoption, it has the potential to play an important
role in modern prostate cancer care.
As with all treatment options, the decision to pursue Vanquish should be based on a thorough evaluation of disease characteristics, patient priorities, and a detailed discussion with an experienced prostate cancer specialist who can guide individualized care.
